Compare AGCO Corporation (AGCO) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGCO Corporation vs Viatris Inc — how do they compare? AGCO Corporation trades at $101.58 (market cap $7.10B), while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 2.6× AGCO Corporation's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| AGCO | VTRS | |
|---|---|---|
Market Cap | $7.10B | $18.69B |
Sector | Industrials | Health |
52-Week High | $140.49 | $17.86 |
52-Week Low | $100.14 | $9.49 |
Enterprise Value | $9.37B | $30.80B |
Dividend Yield | 1.18% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGCO trades at $101.58, up 0.7% today, but remains under pressure after a Q2 2026 earnings miss and lowered full-year guidance triggered an 11% sell-off in late July 2026. The stock shows bearish technical signals with support near $99 and resistance at $102. Fundamentally, 2025 revenue was $10.08B with a net income margin of 7.2%, but 2026 projections indicate softer profitability. Recent leadership changes and ongoing securities investigations add uncertainty, though the consensus price target of $124.63 suggests potential upside from current levels.
The outlook is cautious due to weaker agricultural demand and earnings volatility. Investment appeal hinges on execution of the PTx growth strategy and margin recovery, but risks include legal probes and cyclical industry headwinds. Analyst sentiment is mixed with 38% buy ratings, reflecting divided views on near-term recovery prospects.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AGCO Corporation
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
